Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer
{{output}}
Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype (ER-/PR-/HER2-), is characterized by rapid proliferation, high metastatic rate and frequent recurrence. The development of targeted therapies for TNBC, such as antibody-drug conjug... ...
